| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8945184 | Gynecologic Oncology | 2018 | 8 Pages |
Abstract
Car-RT showed a poorer tumor response and a trend toward inferior survival compared with Cis-RT in the treatment of cervical cancer. However, this evidence was limited by the imbalance among studies. Due to the encouraging efficacy and low toxicity, carboplatin is a suitable concurrent agent for patients with contraindications to cisplatin.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Renliang Xue, Xiumei Cai, Hongyao Xu, Shengxi Wu, Hecheng Huang,